MeWoHomo sapiens (Human)Cancer cell line
Also known as: MEWO, Mewo, Me Wo, Me-Wo, Mevo, SK-MEL-MeWo, Mel-MeWo, BI-Mel, EST50
Quick Overview
Human melanoma cell line used in cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_0445 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Lymph node[UBERON:UBERON_0000029] |
Donor Information
| Age | 78 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Cutaneous melanoma |
|---|---|
| Lineage | Skin |
| Subtype | Cutaneous Melanoma |
| OncoTree Code | SKCM |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000987_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| Gene deletion | CDKN2B | - | Homozygous | - | PubMed=35933914 |
| MutationSimple | CDKN2A | p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT) | Unspecified | - | PubMed=23851445 |
| MutationSimple | FGFR1 | p.Pro252Ser (c.754C>T) | Unspecified | - | PubMed=23851445 |
| MutationSimple | MAPK3 | p.Pro246Ser (c.736C>T) | Heterozygous | - | from parent cell line MeWo |
| MutationSimple | TP53 | p.Gln317Ter (c.949C>T) | Unspecified | - | PubMed=16541312 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Malignant melanoma. Current status of the search for melanoma-specific antigens.
Houghton A.N., Oettgen H.F., Old L.J.
(In book chapter) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston; USA (1981).
Membrane associated antigens of human malignant melanoma V: Serological typing of cell lines using antisera from nonhuman primates.
Bruggen J., Sorg C., Macher E.
Cancer Immunol. Immunother. 5:53-62(1978).
Expression of surface antigens and its relation to parameters of malignancy in human malignant melanoma.
Bruggen J., Macher E., Sorg C.
Cancer Immunol. Immunother. 10:121-127(1981).
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
Fogh J., Fogh J.M., Orfeo T.
J. Natl. Cancer Inst. 59:221-226(1977).
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
Fogh J., Wright W.C., Loveless J.D.
J. Natl. Cancer Inst. 58:209-214(1977).
Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens.
Shiku H., Takahashi T., Oettgen H.F., Old L.J.
J. Exp. Med. 144:873-881(1976).
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.
Old L.J.
Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976).
Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin.
Nip J., Shibata H., Loskutoff D.J., Cheresh D.A., Brodt P.
J. Clin. Invest. 90:1406-1413(1992).
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression.
Kerbel R.S.
Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991).
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
Wright W.C., Daniels W.P., Fogh J.
J. Natl. Cancer Inst. 66:239-247(1981).
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma.
Old L.J.
Proc. Natl. Acad. Sci. U.S.A. 77:4260-4264(1980).
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
J. Natl. Cancer Inst. 66:1003-1012(1981).
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.
Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., Old L.J.
J. Exp. Med. 156:1755-1766(1982).
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Rousset M., Zweibaum A., Fogh J.
Cancer Res. 41:1165-1170(1981).
Characterization of gene regulatory elements for selective gene expression in human melanoma cells.
Artuc M., Nurnberg W., Czarnetzki B.M., Schadendorf D.
Biochem. Biophys. Res. Commun. 213:699-705(1995).
Comet assay studies of radiation-induced DNA damage and repair in various tumour cell lines.
Muller W.-U., Bauch T., Streffer C., Niedereichholz F., Bocker W.
Int. J. Radiat. Biol. 65:315-319(1994).
Screening the p53 status of human cell lines using a yeast functional assay.
Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Mol. Carcinog. 19:243-253(1997).
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Fountain J.W.
Genes Chromosomes Cancer 22:157-163(1998).
High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
Garrido F.
Cancer Immunol. Immunother. 54:141-148(2005).
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.
Guldberg P., Borg A.
Oncogene 26:4738-4748(2007).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARbeta signaling.
Borg A., Pawelec G., Guldberg P.
Mol. Cancer Res. 11:1166-1178(2013).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
Gloger A., Ritz D., Fugmann T., Neri D.
Cancer Immunol. Immunother. 65:1377-1393(2016).